相关实验视频

Updated: Jun 11, 2025

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

皮肤外皮生长因子受体氨酸激酶抑制剂在癌症:当前的使用和未来的前景

Henry Dickerson¹, Ahmad Diab¹, Othman Al Musaimi^1,2

¹School of Pharmacy, Newcastle University, Newcastle upon Tyne NE1 7RU, UK.

International journal of molecular sciences

|September 28, 2024

概括

氨酸激酶抑制剂 (TKIs) 代表了先进的癌症治疗,新一代克服了耐药性并改善了患者的生存率. 研究继续解决像C797S这样的新兴突变,以提高疗效.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
分子生物学分子生物学

背景情况:

氨酸激酶抑制剂 (TKIs) 是向癌症治疗的基石,与传统化疗相比,它们提供了更好的结果和更少的副作用.
对TKI的耐药性,通常是由表皮生长因子受体 (EGFR) 突变驱动的,导致了多个TKI代的发展.

研究的目的:

审查EGFRTKI治疗的进展,详细介绍其作用机制和不同TKI世代在克服耐药性的演变.
分析连续几代TKI对EGFR突变的有效性,包括T790M和新出现的C797S突变.

主要方法:

对EGFRTKI的临床试验和研究研究的文献综述.
对不同TKI代和治疗方案的无进展生存 (PFS) 数据的分析.
对特异性EGFR耐药突变的TKI疗效的评估,如T790M和C797S.

主要成果:

第一代TKIs (例如,gefitinib) 显示PFS比化疗更好. 与第一代药物相比,第二代TKI (例如,阿法替尼) 显示出更高的疗效.
第三代TKI显著增加了生存率,并且对T790M突变有效.
新兴研究表明,第三代TKI可能对具有C797S突变的非小细胞肺癌 (NSCLC) 无效,需要进一步调查.

结论:

EGFR TKI已经取得了显著的进步,每一代都提供了更高的疗效和更好的患者结果.
克服耐药性,特别是对像C797S这样的新突变的抗药性,仍然是TKI疗法的持续研究和开发的关键领域.
虽然针对C797S的新方法存在有希望的体外和体内结果,但需要进一步的临床试验才能获得监管部门的批准.

关键词:

在NSCLCLC中,我们可以看到.亚法提尼布 (Afatinib) 是一种皮肤表皮生长因子受体.盖菲提尼布 (gefitinib) 是一种药物.铁氨基激酶抑制剂铁氨基激酶抑制剂

更多相关视频

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Transducer Mechanism: Enzyme-Linked Receptors

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Receptor Tyrosine Kinases

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...